Global Osteoporosis Drugs Market Size (2024 - 2029)

The osteoporosis drugs market is anticipated to experience growth due to several factors, including the increasing incidence of osteoporosis and the potential therapeutic benefits of osteoporosis treatments in managing COVID-19. The market's expansion is further supported by rising investments in research and development by biotechnology and pharmaceutical companies, which are exploring new treatment options. However, the market's growth is challenged by stringent government regulations.

Home Market Analysis Healthcare Research Pharmaceuticals Research Disease Specific Drugs Research Chronic Disorder Drugs Research Orthopedic Drugs Research Osteoporosis Drugs Industry Market Size

Market Size of Global Osteoporosis Drugs Industry

Osteoporosis Drugs Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
CAGR 3.40 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

Osteoporosis Drugs Market Major Players

*Disclaimer: Major Players sorted in no particular order

Osteoporosis Drugs Market Analysis

The osteoporosis drugs market is expected to record a CAGR of 3.4% during the forecast period (2022-2027).

Many therapies are being followed worldwide to find reliable COVID-19 treatments. Numerous studies have suggested that in addition to drugs used to treat infections, other drugs such as the drug osteoporosis may be helpful in the treatment of COVID-19, which may boost the market. For example, according to a study published in November 2020, "General treatment of osteoporosis may help reduce the incidence of COVID-19", treatments such as denosumab, zoledronate, and calcium, are used to treat osteoporosis and COVID-19. The study was conducted by the Pompeu Fabra University, Hospital del Mar Medical Research Institute (IMIM), and Pere Virgili Health Park. According to research, treatment with osteoporosis can reduce COVID-19 infection by 30-40%.

A major factor in the market's growth is an increase in the incidence of osteoporosis. According to the study titled "Spread and experience of diagnosing osteoporosis in postmenopausal women over the age of 50: Focus on social issues", published in March 2021, the prevalence of osteoporosis was 34.8%, with a diagnosis rate of 22.1% in South Korea, the highest. The increase in the number of young people worldwide prone to bone growth is another important factor in the market's growth. For example, according to the International Osteoporosis Foundation, in 2020, 1 in 5 men and 1 in 3 women over the age of 50 may experience osteoporosis fractures in their remaining life.

In addition, the growing investment in R&D by biotechnology and pharmaceutical companies is enhancing the market's growth. For example, in October 2020, the Italian pharmaceutical authority approved the testing of human clinics with raloxifene. It is a standard orthopedic drug that may help reduce the symptoms of COVID-19. Therefore, positive results from clinical trials can lead to new treatment options, thus boosting the market's growth. However, strict government regulations are hindering the growth of the market studied.

Osteoporosis Drugs Industry Segmentation

As per the scope of the report, osteoporosis makes a person's bones weak and more likely to break. The market is segmented by drug type, application, and geography. The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the market size and forecast in value (USD billion) for the above segments.

By Drug Type
Parathyroid Hormone Therapy
Bisphosphonates
Calcitonin
RANKL Inhibitors
Other Drug Types
By Application
Primary Osteoporosis
Secondary Osteoporosis
By Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Global Osteoporosis Drugs Market Size Summary

The osteoporosis drugs market is poised for steady growth, driven by an increasing prevalence of osteoporosis and the rising incidence of bone-related issues among younger populations. The market is experiencing a boost from the potential use of osteoporosis treatments in managing COVID-19, as studies suggest these drugs may reduce infection rates. The development and approval of new therapies, such as raloxifene, and the ongoing research into the efficacy of Rank ligand inhibitors are further propelling market expansion. These inhibitors, known for their positive impact on bone metabolism and mineral density, are gaining traction due to their potential synergistic effects when combined with other treatments. However, the market's growth is tempered by stringent regulatory challenges.

North America is expected to maintain its dominance in the osteoporosis drugs market, supported by a robust healthcare infrastructure, a high prevalence of osteoporosis, and the presence of key industry players. The United States, in particular, holds a significant market share, attributed to its large adult population and collaborative efforts to enhance medical standards. The COVID-19 pandemic has disrupted treatment protocols, prompting organizations like the American Society for Bone and Mineral Research to issue guidelines to ensure continuity of care. The competitive landscape is marked by the presence of major companies such as Pfizer, Eli Lilly, and Merck, which are engaging in strategic collaborations, high R&D investments, and product innovations to sustain their market positions.

Explore More

Global Osteoporosis Drugs Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Increasing Incidences of Osteoporosis

      2. 1.2.2 Rise in the Geriatric Populations

    3. 1.3 Market Restraints

      1. 1.3.1 Stringent Regulatory Environment

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 2.1 By Drug Type

      1. 2.1.1 Parathyroid Hormone Therapy

      2. 2.1.2 Bisphosphonates

      3. 2.1.3 Calcitonin

      4. 2.1.4 RANKL Inhibitors

      5. 2.1.5 Other Drug Types

    2. 2.2 By Application

      1. 2.2.1 Primary Osteoporosis

      2. 2.2.2 Secondary Osteoporosis

    3. 2.3 By Geography

      1. 2.3.1 North America

        1. 2.3.1.1 United States

        2. 2.3.1.2 Canada

        3. 2.3.1.3 Mexico

      2. 2.3.2 Europe

        1. 2.3.2.1 Germany

        2. 2.3.2.2 United Kingdom

        3. 2.3.2.3 France

        4. 2.3.2.4 Italy

        5. 2.3.2.5 Spain

        6. 2.3.2.6 Rest of Europe

      3. 2.3.3 Asia-Pacific

        1. 2.3.3.1 China

        2. 2.3.3.2 Japan

        3. 2.3.3.3 India

        4. 2.3.3.4 Australia

        5. 2.3.3.5 South Korea

        6. 2.3.3.6 Rest of Asia-Pacific

      4. 2.3.4 Middle-East and Africa

        1. 2.3.4.1 GCC

        2. 2.3.4.2 South Africa

        3. 2.3.4.3 Rest of Middle-East and Africa

      5. 2.3.5 South America

        1. 2.3.5.1 Brazil

        2. 2.3.5.2 Argentina

        3. 2.3.5.3 Rest of South America

Global Osteoporosis Drugs Market Size FAQs

The Global Osteoporosis Drugs Market is projected to register a CAGR of 3.40% during the forecast period (2024-2029)

Eli Lily and Company, F. Hoffmann La Roche, Pfizer Inc., Merck & Co. Inc. and Amgen Inc. are the major companies operating in the Global Osteoporosis Drugs Market.

Osteoporosis Treatment Market Report Snapshots

Osteoporosis Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)